In March 2016, Roseola, the viral infection of babies born with the rare genetic disorder Roseola syndrome, was identified in India.
It quickly spread throughout the world, infecting more than 2 million people and forcing more than 8 million people to undergo medical treatment.
The disease is caused by the Roseola virus, and Roseola is transmitted through the air.
In India, the infection has led to the deaths of nearly 500,000 people, most of them infants.
Now, India is facing a wave of roseola cases, and as more cases are confirmed, India’s health ministry is pushing to introduce a vaccine.
The vaccine, dubbed Roseola II, is a combination of the two vaccines.
But a recent study published in the Lancet Infectious Diseases journal suggests the vaccine will not work.
The study, led by an international team of scientists, looked at the impact of Roseola vaccine on newborns born in India in February and March.
They found the Roseia II vaccine was less effective in reducing the number of infected newborns.
“While the effectiveness of the vaccine was evaluated in the current trial, there was a lack of robust evidence on its efficacy in a large, long-term trial,” the researchers wrote.
This was especially notable because it was not the first time the team had looked at Roseola vaccines.
In February 2017, researchers reported that a Roseola-specific vaccine called Roseola 3.0 had been shown to reduce the number and severity of respiratory infections in newborns, while another vaccine called Roseola 6.0 showed little benefit.
The researchers noted that Roseola 4.0, which is currently in clinical trials, had been tested in a study of 1,300 children in South Africa and the United States, which found a statistically significant reduction in the number, severity, and frequency of infections.
The scientists did note, however, that the Roseolas vaccine does not have enough data to be able to say whether it was the best vaccine available.
Meanwhile, India continues to fight the spread of Roseolas, and a vaccine is in the works.
India has reported nearly 20,000 cases of Roseolas since the vaccine went into trial, but the disease is still very rare in India, where only 2,000 new cases were reported in 2014.
Roseolas have also spread to India’s other states, including Punjab and Haryana, and have caused more than 4,000 deaths.
In response to the new findings, India has begun to introduce mandatory vaccination, with the government now requiring every newborn child in the country to be vaccinated.